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ARID3a/Bright is a DNA-binding protein that was originally discovered for its ability to
increase immunoglobulin transcription in antigen-activated B cells. It interacts with DNA as
a dimer through its ARID, or A/T-rich interacting domain. In association with other proteins,
ARID3a increased transcription of the immunoglobulin heavy chain and led to improved
chromatin accessibility of the heavy chain enhancer. Constitutive expression of ARID3a in
B lineage cells resulted in autoantibody production, suggesting its regulation is important.
Abnormal ARID3a expression has also been associated with increased proliferative capacity
and malignancy. Roles for ARID3a in addition to interactions with the immunoglobulin locus
were suggested by transgenic and knockout mouse models. Over-expression of ARID3a
resulted in skewing of mature B cell subsets and altered gene expression patterns of fol-
licular B cells, whereas loss of function resulted in loss of B1 lineage B cells and defects
in hematopoiesis. More recent studies showed that loss of ARID3a in adult somatic cells
promoted developmental plasticity, alterations in gene expression patterns, and lineage
fate decisions. Together, these data suggest new regulatory roles for ARID3a. The genes
influenced by ARID3a are likely to play pivotal roles in lineage decisions, highlighting the
importance of this understudied transcription factor.
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Bright (B cell regulator of immunoglobulin heavy chain tran-
scription) is a 70 kDa DNA-binding protein first characterized
in the mouse as a component of a protein complex associated
with increased transcription of the immunoglobulin heavy chain
(IgH) locus in activated B lymphocytes (1–3). Bright, also known
as DRIL1, E2FBP1, or ARID3a (the designation for the human
ortholog, hereafter referred to as Bright), is a member of the A+T
rich interaction domain (ARID) protein family, many of which
have been shown recently to have epigenetic regulatory functions
[reviewed in Ref. (4–6)]. These proteins bind to A+T rich DNA
sequences and are typically members of larger chromatin modula-
tory complexes. Bright, and other ARID3 family members, require
dimerization for DNA-binding activity and contain an extended
DNA-binding domain that confers increased DNA sequence speci-
ficity to these proteins compared to other ARID family members
(7–9). Although Bright was the first member of this family iden-
tified in mammalian cells, its functions have only begun to be
elucidated. Previously, Bright expression in adult, mouse, and
human cells was thought to be largely restricted to B lympho-
cyte lineage cells. However, more recently, we and others have
shown that Bright plays important regulatory functions in early
hematopoiesis. Although Bright expression is restricted in adults,
it is more widely expressed in the embryo/fetus and plays impor-
tant regulatory roles in embryonic stem cell differentiation (10).
These data also highlight novel roles for Bright in gene repres-
sion. This article will emphasize the regulatory roles of Bright in
hematopoiesis and will summarize new contributions pertaining
to its regulatory capacity in those and other cell types.
BRIGHT AND HSCs
From a historical perspective, the majority of studies involv-
ing Bright have aimed at understanding its roles in B lympho-
cytes. However, recent evidence suggests Bright may play an even
broader role in the development of hematopoietic lineage cells.
Hematopoietic stem cells (HSCs) have the capacity to self-renew or
to differentiate into other precursors that will eventually produce
all mature blood cell types. Differentiation of hematopoietic prog-
enitors occurs primarily along three pathways: erythroid, myeloid,
and lymphoid lineages (Figure 1). An intricate network of tran-
scription factors contribute to HSC fate decisions, with more than
20 transcription factors implicated in the development of vari-
ous hematopoietic subpopulations [reviewed in Ref. (11)], such
as growth factor independence 1 (Gfi1), E2A, and Ikaros fam-
ily zinc-finger protein 1 (Ikaros) in lymphoid lineage regulation;
CCAAT-enhancer binding protein alpha (C/EBPα), GATA1, and
PU.1 for myeloid lineage decisions [reviewed in Ref. (11–13)].
Bright is expressed in HSCs in both mouse and man [(14–16); and
our unpublished data] and appears to be required for development
of several early progenitor subsets including multipotent prog-
enitors (MPPs) and lymphoid-primed MPP (LMPP) (Figure 1).
Therefore, Bright contributes to early progenitor ontogeny, which
may ultimately affect the development of multiple lineages.
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FIGURE 1 | Bright expression in hematopoiesis. Hematopoietic progenitor
populations [as described (11)] indicate stages, which express Bright/ARID3a
(red font) versus those not known to express Bright (black font). Thick red
arrows indicate stages of developmental progression for which Bright
function is important. HSC, hematopoietic stem cell; MPP, multipotent
progenitor; LMPP, lymphoid-primed multipotent progenitor; CMP, common
myeloid progenitor; CLP, common lymphoid progenitor; GMP,
granulocyte-macrophage progenitor; MEP, megakaryocyte–erythrocyte
progenitor; BCP, B cell progenitor; TCP, T cell progenitor; NKP, NK cell
progenitor; MP, macrophage progenitor; GP, granulocyte progenitor; EP,
erythrocyte progenitor; MkP, megakaryocyte progenitor; BAS, basophils; NE,
neutrophils; MC, mast cells; EOS, eosinophils.
Bright knockout mice die between E11.5 and E13.5 as a result
of defects in erythroid lineage differentiation (16). Bright knock-
out embryos have severe pallor and show fewer mature erythro-
cytes by flow cytometry. Embryonic death in Bright-deficient
mice coincides with the shift from primitive hematopoiesis in
the yolk sac to definitive hematopoiesis in the fetal liver. Num-
bers of fetal liver lin−cKithiSca1+CD150+CD48− HSCs in these
embryos were reduced by >90%, while LSKs (Lin−Sca1+cKit+
cells that include HSC and MPP populations) were decreased in
Bright deficient versus wild-type littermate controls by 80% (16).
Numbers of common myeloid progenitors (CMPs) and common
lymphoid progenitors (CLPs) were also decreased in Bright knock-
out fetal livers, but to a lesser degree. This suggests that Bright
may have greater effects in HSCs than in later precursor subsets.
Bright knockout fetal liver cells were also impaired in their abil-
ity to generate erythroblast, erythromyeloid, and B lymphocyte
colonies in in vitro methylcellulose cultures compared to wild-type
cells (16). Therefore, Bright may also contribute to the expan-
sion and development of these hematopoietic cells. Importantly,
these data confirm the importance of Bright for normal erythroid
differentiation.
Rare Bright knockout mice (<1%) survived to adulthood for
unknown reasons. These adult Bright-deficient mice exhibited
reduced numbers of hematopoietic precursors in the bone mar-
row, including LSK, CMP, and CLP subsets, but to a lesser degree
than was observed in Bright null embryos (16). Although adult
Bright-deficient mice showed decreased numbers of several early
B cell subsets, interestingly, no deficiencies in T cell or erythro-
cyte development were observed (16). The importance of Bright
in other hematopoietic lineages has not been fully explored; how-
ever, recent data from The Immunological Genome Project suggest
Bright transcripts are expressed in mouse neutrophils where its
function is unclear (17). Currently, our data from knockout mouse
models suggest that the function of Bright in adult bone mar-
row may be more critical for the development of B lymphocytes
and early precursor subpopulations of those cells than for other
hematopoietic cell types.
BRIGHT SIDE OF B CELLS
Common lymphoid progenitors give rise to early subpopulations
of precursor B cells (Figure 2), which eventually develop through
multiple differentiation states in both the bone marrow and the
periphery to result in fully differentiated,mature B cells. Pro-B cells
express RAG1/2 gene products, and rearrange IgH gene segments
(18, 19), and in man, they are the first B cell progenitors to tran-
scribe Bright (14). Bright expression occurs in both mouse and
human subsets of pre-B cells, transitional B cells, activated and
memory B cells, and plasma cells (14, 15) (Figure 2). However,
the majority of resting, naïve, and mature, peripheral B lympho-
cytes do not express Bright as evidenced by the absence of Bright
transcripts in the majority of circulating blood cells in man, and
in follicular spleen cells in the mouse (14, 15). Both human and
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FIGURE 2 | Bright expression during B lymphopoiesis. Gray cells
indicate B lineage subsets not known to express Bright. Purple subsets
express Bright, while lighter shades (T2, MZ B, and B1 B) represent
slightly lower levels of Bright expression. Bright is required for
development of B1 B cells indicated by red hash marks. Bolded arrow
indicates developmental skewing caused by Bright over-expression. CLP,
common lymphoid progenitor; MZ B, marginal zone B cells; FO B, follicular
B cell; GC B, germinal center B cells.
mouse innate-like B cells, represented by peritoneal cavity B1 B
lymphocytes and splenic marginal zone (MZ) B lymphocytes in
mice, and by B1-like and MZ-like cells in human peripheral blood
[reviewed in Ref. (20, 21)], express low levels of Bright [(22);
unpublished data]. Thus, Bright expression is tightly regulated
at the level of transcription throughout B cell differentiation.
Transgenic mice expressing a dominant negative form of Bright
from the CD19 pan-B cell promoter were generated by introduc-
tion of point mutations in the DNA-binding domain to test the
function of Bright within B lineage cells (8, 22). These transgenic
mice had slightly decreased numbers of mature B cells, decreased
serum IgM levels, and defective responses against Streptococci (22),
phenotypes similar to those observed in Bruton’s tyrosine kinase
(Btk) deficient mice [(23), reviewed in Ref. (24, 25)]. Although
these mice developed mature B1 B cells, a major source of IgM
in the mouse, those cells were functionally defective in their abil-
ity to secrete immunoglobulin (22). Furthermore, the few total
Bright knockout mice that survived to adulthood lacked B1 B cells
(16), suggesting Bright is important both for development and
function of those mature B cells. Adult Bright-deficient mice also
showed impaired T cell-dependent IgG1 production due to defects
in class switch recombination (16). Thus, Bright contributes to
select functions in mature B cells.
Forced expression of native Bright throughout the B cell lineage
suggested that regulation of Bright is critical for normal devel-
opment of MZ and follicular B cells. Transgenic FVB/N mice
constitutively over-expressing Bright from the CD19 promoter
exhibited significant increase in immature transitional B and MZ
B cells relative to the other splenic B cell populations (26). On
the C57BL/6 background, over-expression of Bright also resulted
in decreased numbers of follicular (FO) B cells (27). The FO B
cells that were present in those mice displayed transcript levels
of genes previously shown to be differentially expressed in FO
versus MZ B cells (28) that were similar to those observed in
MZ B cells. Chimeras generated from mixtures of transgenic and
wild-type bone marrow cells also showed preferential develop-
ment of MZ versus FO B cells (27), suggesting that constitutive
Bright expression contributes preferentially to MZ versus FO B
cell development.
Bright expression can be induced in mature resting B cells
through a number of activating signals, including stimulation with
lipopolysaccharide (LPS), CD40 ligand, interleukin-5 (IL-5) plus
specific antigen, and with agonistic monoclonal antibodies against
CD38 or RP105 (2, 3, 15). Additionally, Epstein–Barr Virus (EBV)
infection also activates Bright expression in human B cells (14).
Although the function of Bright in B lymphocytes was thought to
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be exerted primarily in the nucleus via interactions with A+T-rich
DNA sequences, a very small percentage of Bright was discovered
to be palmitoylated and diverted to lipid rafts (29). In vitro stud-
ies demonstrated Bright localization to these rafts increased the
signaling threshold of the B cell receptor (BCR). Upon effective
activation, Bright was released from the lipid rafts via SUMOyla-
tion. Interestingly, Btk remained unphosphorylated when Bright
was present, delineating a putative role for Bright in BCR signal-
ing (29). However, FO B cells from transgenic mice with forced
expression of Bright did not have elevated levels of Bright in lipid
rafts, in contrary to transitional and MZ B cell populations, nor
did they have alterations in their ability to flux calcium through the
BCR. Together, these data suggested other cell type-specific factors
may contribute to Bright-mediated effects through the BCR (27).
GENE TARGETS FOR BRIGHT
It was originally observed that stimulation of an antigen-specific
mouse B cell line with antigen and IL-5 resulted in an increase in
immunoglobulin (µ) heavy chain transcription. Further analyses
identified two discrete A+T rich elements within the V1 S107
variable heavy chain promoter were bound by a protein complex
later identified to contain Bright (3). Intriguingly, further analy-
ses showed potential Bright-binding motifs in about half of the
murine VH promoters, and binding sites were not restricted to spe-
cific V region families (30, 31). Similarly, only a subset of human
VH promoters had binding sites for Bright (32). These data sug-
gest that Bright may preferentially affect transcription of a subset
of IgH genes.
In the mouse, the intronic enhancer of the IgH gene is flanked
by 5′ and 3′ A+T rich regions called matrix associated regions
(MARs) that act to tether DNA to the nuclear matrix. Promoter
binding sites for Bright were shown to have MAR activity (1), and
conversely, Bright was shown to bind to the MARs of the intronic
IgH enhancer in the mouse (7). Mouse and human IgH enhancers
are similar, but not identical, showing some differences in binding
sites for several transcription factors (Figure 3). Bright-binding
sites flank both the mouse and human enhancer core sequences.
Although Bright did not directly activate transcription of the IgH
enhancer regions in vitro, in contrast to promoter fragments that
bound Bright (33), MAR regions bound by Bright have been pro-
posed to play important roles establishing chromatin domains
important for expression. Indeed, the intronic enhancer region in
the mouse locus has been shown to be important for chromatin
remodeling, and binding of Bright to sites flanking that region
correlated with increased enhancer accessibility (34). Bright can
also form tetramers and was found to enhance DNA-bending,
suggesting it may also contribute to higher order structures link-
ing the intronic enhancer to specific VH region promoters (35).
Therefore, we speculate that Bright, like other members of the
ARID family, may contribute to epigenetic regulation of the IgH
locus.
Recently, additional gene targets for Bright have been identified.
Bright was shown to bind to the core promoter sequence of the
EBV C promoter (Cp) where it interacts with E2F-1 and Oct-2, and
to the family of repeats (FR) region at the latent origin of plasmid
replication (oriP) in the EBV plasmid (36). Cp regulates expression
of genes required for B cell proliferation in latent EBV infections.
The FR regions are upstream of Cp, functioning as an essen-
tial enhancer to this promoter, and this interaction is mediated
by Epstein–Barr nuclear antigen 1 (EBNA1) (37). Together, these
interactions lead to the initiation of transcription of EBV latency
proteins (36), suggesting that Bright contributes to maintenance
of EBV in certain B cell subsets.
Additional putative gene targets for Bright/ARID3a have been
identified as part of the ENCODE project, and that database now
lists a number of potential gene targets for Bright/ARID3a in
human cell lines (38). One target of particular interest is Oct4. We
found that Bright binds to the Oct4 promoter and acts to repress
its transcription in mouse embryonic fibroblasts (39). These data
are the first to indicate Bright can have repressive as well as activat-
ing functions, such as those described for the IgH locus. Further,
the Drosophila ortholog of Bright, Dril1, recruits Groucho to Dor-
sal where it is also associated with strong repressive potential (6).
It is likely that Bright levels will affect multiple gene targets in
hematopoietic cells, where it will be important to consider that it
may also act to suppress gene expression.
FIGURE 3 | Bright binds to sequences flanking the mouse and human IgH enhancer. Schematic diagrams of fragments including the Eµ core enhancer
show binding site for E proteins, Ets proteins (µA, µB, HE2), and Oct transcription factors. Matrix association regions (MARs) identified by MAR-binding assays
are indicated by red stars on either side of the core (1). Orange enhancer elements denote those regions that are not conserved between species.
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CO-REGULATORY AND INTERACTING PROTEINS
Dimerization of Bright was required for binding to the IgH locus
in mobility shift assays (8). Earlier antibody supershift assays were
the first to suggest that the Bright complex might also contain
additional proteins, potentially including topoisomerase II (40).
The S107 VH gene, containing the prototypic Bright-binding site,
was required for immune responses against phosphorylcholine,
a response deficient in mice lacking Btk [Ref. (23), reviewed in
Ref. (24, 25)]. These data led to experiments demonstrating that
Btk interacted directly with Bright, and that its kinase activity
was required for Bright-associated transactivation of the IgH pro-
moter (41). Further studies demonstrated that the transcription
factor TFII-I, a Btk target [reviewed in Ref. (42)], also bound to
Bright through the helix-turn helix domain at the carboxyl end
of Bright, and that this interaction was also required for activa-
tion of the immunoglobulin locus (33). TFII-I is ubiquitously
expressed in multiple isoforms and functions as a transcription
factor for basally expressed genes and a transcription activator for
upstream protein complexes [reviewed in Ref. (42)]. This suggests
that Bright may act as a DNA-binding component to recruit or
tether other transcription activating proteins to specific promoter
sites.
A truncated form of human Bright/ARID3a was cloned and
identified by others from embryonal carcinoma cells as an E2F-
binding protein, E2FBP1 (43). These studies showed interactions
of Bright and E2F-1, a pRB-controlled protein important for cell
cycle regulation, and linked Bright function to cell cycle regu-
lated functions. Functional screens for products that rescued Ras-
induced senescence in mouse embryonic fibroblasts also identified
Bright (hDril1) as a candidate protein (44). Those studies also
linked Dril1/Bright functions to proliferation and pRB-mediated
pathways; however, results using human cells did not mirror those
observed in mouse embryonic fibroblasts. In other model systems
that required p53, Bright over-expression induced G1 arrest by
activating p21 in response to DNA damage in human osteosar-
coma cells (45). In this and other studies, ARID3a was found to
be a direct downstream target of p53, and a co-regulator with
p53 of other gene targets (45, 46). The multiple roles played by
Bright/ARID3a during the cell cycle in different cell types high-
light the necessity to use caution in interpreting data that may be
of a complex nature and the result of interactions with different
intracellular mediators. Interpretation of studies involving over-
expression of Bright may be further complicated, as levels of Bright
within cells of the same lineage appear to be tightly regulated as
a consequence of the differentiation state (14). Indeed, SUMOy-
lation of Bright was reported to impair interactions with E2F-1
while promoting transcriptional activation of myeloid lineage-
specific genes in HSC populations (47), indicating further com-
plexities that may exist in some cell types due to post-translational
modifications of Bright and/or the proteins with which it may
interact.
Bright has also been shown to interact with several components
of promyelocytic leukemia nuclear bodies (PML NBs), includ-
ing the ubiquitously expressed protein SP100 and the lymphoid-
restricted homolog, LYSp100B (48). Bright was found to colocalize
with Sp100 in PML NBs and was found to repress Bright trans-
activation functions, while LYSp100 strongly stimulated Bright
transactivation of the IgH locus. These data support functions for
Bright in higher order chromatin topology and epigenetic reg-
ulation. Other studies suggest that levels of Bright/E2FBP1 are
important for maintenance of PML NBs and cell viability (49, 50).
Some viral proteins, including those from human herpes simplex
viruses, also disrupt PML NBs and show linked regulatory effects
with Bright/E2FBP1 (51). Clearly, it will be important to under-
stand further consequences of Bright functions in these important
nuclear structures.
Finally, as we continue to see examples of transcription factors
that interact to form large chromatin modulatory complexes or
interactomes that regulate large sets of genes involved in specific
cellular processes, it is likely that we will identify new protein part-
ners for Bright. Recent findings suggest Bright/ARID3a is one of
a number of genes induced by gamma-interferon in Th1 cells, a
T helper cell subset previously unknown to express Bright (52).
These findings emphasize again the likelihood that Bright may
play distinct regulatory roles in different types of cells.
REGULATION OF BRIGHT
Id1, a member of a family of three proteins described to be nega-
tive regulators of E2A proteins (53, 54), was also shown to interact
with Bright/Dril1 in human fetal lung fibroblasts and in lung
fibroblasts from patients with idiopathic fibrosis (55). As with
other factors inhibited by Id proteins, Id1 formed a complex with
Bright that abrogated its DNA-binding activity. In fibrotic lung
tissues, Bright was expressed abundantly as a consequence of TGF-
β signaling (55). Lending further support that Bright may be a
downstream mediator of TGF-β signaling, the Bright ortholog in
Xenopus was required for normal development of mesoderm in
embryos, through SMAD2-dependent TGFβ pathways (56). Fur-
thermore, our lab has observed a link between levels of Bright in
human B lymphocytes and expression of TGF-β pathway associ-
ated genes (our unpublished data), additionally supporting associ-
ations between TGF-β signaling and Bright induction. Id proteins,
important for regulation of Bright in lung tissues (55), have also
been shown to be important in lineage decisions and in directing
B cells toward MZ versus FO B cell phenotypes (57, 58). As men-
tioned previously, we demonstrated that levels of Bright contribute
to those same B cell lineage decisions in transgenic mouse models
(27). Therefore, we speculate that Id proteins may also regulate
Bright during B cell development.
Very little is known regarding Bright regulation. In B lympho-
cyte lineage cells, Bright is tightly regulated during differentiation
at the level of transcription (14). An important microRNA family
regulating transcript levels during hematopoiesis is miRNA125.
This microRNA family consists of three members that function
at different stages of this process. Myeloid lineage fate deci-
sions have been reported to be regulated by miR125b, push-
ing granulocyte-macrophage progenitors for the myeloid lineage
toward macrophage differentiation (59). Previous studies char-
acterized expression of the miR125 family of micro RNAs in
human B lymphocytes at various stages of differentiation, show-
ing members of this family were differentially expressed according
to the maturation state of the cells (60). In addition, these studies
indicated that over-expression of miR125b inhibited B cell differ-
entiation and affected survival of myeloma cells. Although it is
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unclear whether some of these effects may be mediated through
suppression of Bright, others have shown that Bright is a direct tar-
get of miR125b in B cell progenitors (61). Expression of miR125b
in human pre-BI cells increased their proliferation in culture. Sim-
ilar responses were observed in B cell acute lymphocytic leukemias
(B-ALL), where these effects were mediated through suppression
of ARID3a (61). Suppression of ARID3a in those cells also resulted
in decreased apoptosis in a p53-independent fashion. Interestingly,
increased expression of miR125b did not block in vitro pre-B dif-
ferentiation (61). Thus, Bright functions likely differ according to
the maturation state of the B cell.
IMPLICATIONS IN HEALTH AND DISEASE
Because Bright was first identified in B lymphocytes, its func-
tions have been better elucidated in those cells. Over-expression
of Bright in mouse B lineage cells increased production of autoan-
tibodies with anti-nuclear antigen (ANA) specificities (26, 27).
These antibodies formed immunoglobulin deposits in the kidney
glomeruli, although this did not affect kidney function nor did
mice display autoimmune phenotypes that threatened mortality.
These data imply that Bright over-expression in B lineage cells
may predispose those cells toward autoreactive phenotypes, either
by expanding B cells with autoimmune phenotypes or by allow-
ing their escape from important tolerance checkpoints. Increased
numbers of T1 transitional B cells and MZ B cells have been
implicated in autoimmune disease in both mouse and human
and both of these B lineage subsets express Bright (26, 27). ANA
production is a defining characteristic of autoimmune patients
with systemic lupus erythematosus (SLE), and we found that those
patients also show increased numbers of Bright+ peripheral blood
B lineage cells that are associated with increased disease activity
(our unpublished results). Several studies have linked EBV and
SLE, with nearly all pediatric and adult SLE showing EBV infec-
tion [reviewed in Ref. (62)]. Intriguingly, Bright is induced in
human B cells upon infection with EBV (14), and EBV requires
Bright for maintenance of latency genes (36). In addition, many
miRNAs have been noted to be differentially expressed in SLE
patients versus healthy controls, and miR125a, a member of the
family responsible for down-regulation of Bright activity in B
cell progenitors (61), was described as being down-regulated in
lupus lymphocytes [reviewed in Ref. (63)]. Together, these studies
highlight the importance for future mechanistic studies to explore
the links between Bright expression and ANA production in SLE
patients and their relationship to epigenetic changes implicated in
SLE pathology (64).
Bright dysregulation has also been implicated in several types
of malignancies, including those derived from hematopoietic lin-
eage cells. Analyses of diffuse large B cell lymphomas (DLBCL)
over a decade ago identified two distinct subtypes of those malig-
nancies with different survival advantages, the activated B-like
(ABC) and germinal center B-like (GCB) DLBCL by gene expres-
sion profiling, which indicated differential ARID3a expression in
the two subsets (65). More recent large scale comparative analyses
of gene expression patterns in >2000 cases of DLBCL identified
Bright/ARID3a as a member of a family of transcription factor
signature genes consistently associated with ABC DLBCL, sug-
gesting it might be a useful marker for identification of this subset
of lymphoma (66). To the contrary, in the pre-B cell malignancy,
B-ALL, Bright expression was down-regulated compared to levels
found in healthy pre-B cells as a consequence of 30- to 600-fold
higher expression of miR125b, resulting in the oncogenic prop-
erties of increased proliferation and cell survival (61). These data
suggest that dysregulated Bright/ARID3a levels may contribute
to malignancy. This may not be surprising in light of associa-
tions between Bright, p53, and other critical cell cycle mediators
described above. In keeping with the multiple advances describ-
ing additional cell types expressing ARID3a, recent studies also
indicate that high levels of Bright/ARID3a may distinguish col-
orectal carcinomas with good prognosis and a more differentiated
phenotype (67).
Interestingly, a B-ALL patient sample with down-regulated lev-
els of Bright was reported to have significant upregulation of
pluripotent factors (61). We previously showed that loss of Bright
expression in mouse B lineage cells up-regulated pluripotency gene
expression and promoted developmental plasticity, giving rise to
cells that resembled induced pluripotent stem cells (10). Many
types of malignancies are proposed to contain adult stem cell pop-
ulations that contribute to their oncogenic potential [reviewed in
Ref. (68)]. Stem cells, as a consequence of their self-renewal prop-
erties, express many genes commonly dysregulated in oncogenesis.
Our recent studies show that Bright knockout mouse embryonic
fibroblasts can spontaneously form stem cell-like colonies and the
key pluripotency factor, Oct4, is repressed as a consequence of
Bright function (39). The ability to reprogram cells from multiple
sources, including hematopoietic lineage cells, by manipulating
expression of Oct4 and other pluripotency-related transcripts has
tremendous potential for regenerative medicine (69). We hypoth-
esize that directed manipulation of Bright levels will also have
useful applications in regeneration of some cell types. The next
decade is full of Bright promise.
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